DK1278730T3 - 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol - Google Patents

4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol

Info

Publication number
DK1278730T3
DK1278730T3 DK01933833T DK01933833T DK1278730T3 DK 1278730 T3 DK1278730 T3 DK 1278730T3 DK 01933833 T DK01933833 T DK 01933833T DK 01933833 T DK01933833 T DK 01933833T DK 1278730 T3 DK1278730 T3 DK 1278730T3
Authority
DK
Denmark
Prior art keywords
piperidine
phenoxy
diol
benzyl
hydroxy
Prior art date
Application number
DK01933833T
Other languages
Danish (da)
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Neidhart Marie-Paule Heitz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1278730T3 publication Critical patent/DK1278730T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01933833T 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol DK1278730T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25

Publications (1)

Publication Number Publication Date
DK1278730T3 true DK1278730T3 (da) 2006-05-01

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01933833T DK1278730T3 (da) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol

Country Status (18)

Country Link
US (1) US6432985B2 (enExample)
EP (1) EP1278730B1 (enExample)
JP (1) JP3831255B2 (enExample)
KR (1) KR100527527B1 (enExample)
CN (1) CN1178914C (enExample)
AR (1) AR028357A1 (enExample)
AT (1) ATE313527T1 (enExample)
AU (1) AU785153B2 (enExample)
BR (1) BR0110233A (enExample)
CA (1) CA2407345C (enExample)
DE (1) DE60116080T2 (enExample)
DK (1) DK1278730T3 (enExample)
ES (1) ES2254422T3 (enExample)
MX (1) MXPA02010573A (enExample)
PE (1) PE20011229A1 (enExample)
UY (1) UY26681A1 (enExample)
WO (1) WO2001081309A2 (enExample)
ZA (1) ZA200208134B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2006515999A (ja) 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
ES2463766T3 (es) 2008-08-12 2014-05-29 Zinfandel Pharmaceuticals, Inc. Método de identificación de factores de riesgo de la enfermedad de Alzheimer
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP3106165B1 (en) 2011-01-10 2019-02-27 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
JP7132218B2 (ja) * 2016-11-08 2022-09-06 エフ．ホフマン－ラ ロシュ アーゲー フェノキシトリアゾール

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
MXPA02010573A (es) 2003-03-10
KR20040007216A (ko) 2004-01-24
WO2001081309A2 (en) 2001-11-01
CN1178914C (zh) 2004-12-08
EP1278730B1 (en) 2005-12-21
AU6021301A (en) 2001-11-07
ZA200208134B (en) 2004-01-22
JP2004509837A (ja) 2004-04-02
AU785153B2 (en) 2006-10-05
DE60116080D1 (de) 2006-01-26
UY26681A1 (es) 2001-10-25
PE20011229A1 (es) 2001-12-08
BR0110233A (pt) 2003-01-21
ES2254422T3 (es) 2006-06-16
CA2407345C (en) 2009-04-07
ATE313527T1 (de) 2006-01-15
JP3831255B2 (ja) 2006-10-11
AR028357A1 (es) 2003-05-07
US6432985B2 (en) 2002-08-13
EP1278730A2 (en) 2003-01-29
CN1443166A (zh) 2003-09-17
KR100527527B1 (ko) 2005-11-09
DE60116080T2 (de) 2006-08-24
CA2407345A1 (en) 2001-11-01
WO2001081309A3 (en) 2002-01-17
US20010047014A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DK1278730T3 (da) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
IS6492A (is) Ný bíarýlkarboxamíð
DE60140969D1 (de) Bankomat
DE60128634D1 (de) Bankautomat
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
IT1320240B1 (it) Macchina curvatrice di profilati.
DE10193450D2 (de) Gehörschutzstöpsel
DE10085473T1 (de) Erodiermaschine
FI4460U1 (fi) Kalanteri
DE50103946D1 (de) Verstellvorrichtung
DE50007064D1 (de) Kalander
DE50102094D1 (de) Kalander
FI20000399A7 (fi) Kalanteri
FR2805883B1 (fr) Profile
FR2803483B1 (fr) Andaineuse frontale
DE50105888D1 (de) Kalander
DE50101830D1 (de) Kalander
FIU20000395U0 (fi) Kalanteri
SE0000045D0 (sv) JIT/JIM-Balk
ATA4452000A (de) Toupet
ES1047939Y (es) Caña de lavado total.
ES1047325Y (es) Rodillo perfeccionado.
ITVE20000004A1 (it) Sonda metrica.